Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions

Modern Pathology

Volumn 26, Issue 7, 2013, Pages 975-983

  Kluth, Martina ^a   Hesse, Jana ^a   Heinl, Anna ^a   Krohn, Antje ^a   Steurer, Stefan ^a   Sirma, Hüseyin ^a   Simon, Ronald ^a   Mayer, Pascale Sophia ^a   Schumacher, Udo ^a   Grupp, Katharina ^a   Izbicki, Jakob R ^a   Pantel, Klaus ^a   Dikomey, Ekkehard ^a   Korbel, Jan O ^b   Plass, Christoph ^c   Sauter, Guido ^a   Schlomm, Thorsten ^a   Minner, Sarah ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

ERG; MAP3K7; prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; ONCOPROTEIN; TMPRSS2-ERG FUSION PROTEIN, HUMAN; TUMOR MARKER;

ALLELE; APOPTOSIS; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; DNA METHYLATION; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE DELETION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; RNA ISOLATION; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE MICROARRAY; ADULT; AGED; BLOOD; CHROMOSOME 6; GENETICS; MALE; MIDDLE AGED; PATHOLOGY; POLYMERASE CHAIN REACTION; PROSTATE TUMOR; TUMOR RECURRENCE; WESTERN BLOTTING;

ADULT; AGED; BLOTTING, WESTERN; CHROMOSOMES, HUMAN, PAIR 6; GENE DELETION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MAP KINASE KINASE KINASES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ONCOGENE PROTEINS, FUSION; POLYMERASE CHAIN REACTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84879947917     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.236     Document Type: Article

References (43)

1. Sun J, Liu W, Adams TS, et al. DNA copy number alterations in prostate cancers: A combined analysis of published CGH studies. Prostate 2007;67:692-700. (Pubitemid 46709438)
2. Taylor BS, Schultz N, Hieronymus H, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
3. Ishkanian AS, Mallof CA, Ho J, et al. High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer. Prostate 2009;69:1091-1100.
4. Liu W, Chang BL, Cramer S, et al. Deletion of a small consensus region at 6q15, including the MAP3K7 gene, is significantly associated with high-grade prostate cancers. Clin Cancer Res 2007;13:5028-5033. (Pubitemid 47502067)
5. Lapointe J, Li C, Giacomini CP, et al. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis. Cancer Res 2007;67:8504-8510. (Pubitemid 47437424)
6. Wu M, Shi L, Cimic A, et al. Suppression of Tak1 Promotes Prostate Tumorigenesis. Cancer Res 2012;72:2833-2843.
7. Delaney JR, Mlodzik M. TGF-beta activated kinase-1: new insights into the diverse roles of TAK1 in development and immunity. Cell Cycle 2006;5: 2852-2855. (Pubitemid 44953934)
8. Edlund S, Bu S, Schuster N, et al. Transforming growth factor-beta1 (TGF-beta)-induced apoptosis of prostate cancer cells involves Smad7-dependent activation of p38 by TGF-beta-activated kinase 1 and mitogenactivated protein kinase kinase 3. Mol Biol Cell 2003;14:529-544. (Pubitemid 36237014)
9. Verheyen EM. Opposing effects of Wnt and MAPK on BMP/Smad signal duration. Dev Cell 2007;13:755-756. (Pubitemid 350163043)
10. Yang YM, Bost F, Charbono W, et al. C-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. Clin Cancer Res 2003;9:391-401. (Pubitemid 36109757)
11. Gunnell LM, Jonason JH, Loiselle AE, et al. TAK1 regulates cartilage and joint development via the MAPK and BMP signaling pathways. J Bone Miner Res 2010;25:1784-1797.
12. Yamaguchi K, Shirakabe K, Shibuya H, et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 1995;270:2008-2011. (Pubitemid 26097194)
13. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103:239-252.
14. Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J 2010;429:403-417.
15. Katoh M. Networking of WNT, FGF, Notch, BMP, and Hedgehog signaling pathways during carcinogenesis. Stem Cell Rev 2007;3:30-38. (Pubitemid 47472809)
16. Saric T, Brkanac Z, Troyer DA, et al. Genetic pattern of prostate cancer progression. Int J Cancer 1999;81:219-224. (Pubitemid 29144750)
17. Cooney KA, Wetzel JC, Consolino CM, et al. Identification and characterization of proximal 6q deletions in prostate cancer. Cancer Res 1996;56:4150-4153. (Pubitemid 26305008)
18. McNeal JE, Redwine EA, Freiha FS, et al. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988;12:897-906. (Pubitemid 19011040)
19. Minner S, Jessen B, Stiedenroth L, et al. Low level HER2 overexpression is associated with rapid tumor cell proliferation and poor prognosis in prostate cancer. Clin Cancer Res 2010;16:1553-1560.
20. Bubendorf L, Kononen J, Koivisto P, et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999;59:803-806. (Pubitemid 29086730)
21. Minner S, Enodien M, Sirma H, et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clin Cancer Res 2011;17:5878-5888.
22. Krohn ADT, Burkhardt L, Mayer PS, et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion positive and fusion negative prostate cancer. Am J Pathol 2012;181: 401-412.
23. Mader M, Simon R, Steinbiss S, et al. FISH Oracle: A web server for flexible visualization of DNA copy number data in a genomic context. J Clin Bioinforma 2011;1:20.
24. Boehm JS, Zhao JJ, Yao J, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007;129:1065-1079. (Pubitemid 46891036)
25. Cuchet D, Sykes A, Nicolas A, et al. PML isoforms I and II participate in PML-dependent restriction of HSV-1 replication. J Cell Sci 2011;124:280-291.
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001;25: 402-408. (Pubitemid 34164012)
27. Zitzer H, Wente W, Brenner MB, et al. Sterol regulatory element-binding protein 1 mediates liver X receptorbeta-induced increases in insulin secretion and insulin messenger ribonucleic acid levels. Endocrinology 2006;147:3898-3905. (Pubitemid 44079395)
28. Vieira SA, Deininger MW, Sorour A, et al. Transcription factor BACH2 is transcriptionally regulated by the BCR/ABL oncogene. Genes Chromosomes Cancer 2001;32:353-363. (Pubitemid 33055120)
29. Miasari M, Puthalakath H, Silke J. Ubiquitylation and cancer development. Curr Cancer Drug Targets 2008; 8:118-123. (Pubitemid 351347247)
30. Leithe E, Sirnes S, Omori Y, et al. Downregulation of gap junctions in cancer cells. Crit Rev Oncog 2006; 12:225-256. (Pubitemid 46524132)
31. Xin L, Lawson DA, Witte ON. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci USA 2005;102:6942-6947. (Pubitemid 40675421)
32. Berger MF, Lawrence MS, Demichelis F, et al. The genomic complexity of primary human prostate cancer. Nature 2011;470:214-220.
33. Berger AH, Pandolfi PP. Haplo-insufficiency: A driving force in cancer. J Pathol 2011;223:137-146.
34. Chen Z, Trotman LC, Shaffer D, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005;436: 725-730. (Pubitemid 41117277)
35. Chen Z, Carracedo A, Lin HK, et al. Differential p53-independent outcomes of p19(Arf) loss in oncogenesis. Sci Signal 2009;2: Ra44.
36. Zhou XZ, Huang P, Shi R, et al. The telomerase inhibitor PinX1 is a major haploinsufficient tumor suppressor essential for chromosome stability in mice. J Clin Invest 2011;121:1266-1282.
37. Mogal AP, van der Meer R, Crooke PS, et al. Haploinsufficient prostate tumor suppression by Nkx3.1: A role for chromatin accessibility in dosage-sensitive gene regulation. J Biol Chem 2007;282:25790-25800. (Pubitemid 47372777)
38. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-4878. (Pubitemid 24289415)
39. Coles C, Condie A, Chetty U, et al. p53 mutations in breast cancer. Cancer Res 1992;52:5291-5298.
40. Kwabi-Addo B, Giri D, Schmidt K, et al. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc Natl Acad Sci USA 2001;98:11563-11568. (Pubitemid 32928768)
41. Abdulkadir SA, Magee JA, Peters TJ, et al. Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol Cell Biol 2002;22: 1495-1503. (Pubitemid 34150785)
42. Kumar A, Shendure J, Nelson PS. Genome interrupted: Sequencing of prostate cancer reveals the importance of chromosomal rearrangements. Genome Med 2011; 3:23.
43. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer 2011;11:481-492.